In a market where clinical timelines and capital discipline increasingly shape sentiment, Bolt Biotherapeutics Inc. (BOLT) has emerged as a name drawing renewed attention.
The stock posted a modest gain of 3.33% in after-hours trading, rising to $6.05 following a 2.36% uptick during the regular session. While the move may appear incremental, it comes amid a series of strategic and clinical updates that signal a recalibration of the company's near-term trajectory.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.